A University of Pittsburgh-led clinical study has reported measurable improvements in light sensitivity for some people with advanced retinitis pigmentosa, an inherited disease that can lead to blindness. The experimental approach combined a one-time gene-therapy injection with specialized goggles; the small study found encouraging early results, not a cure or a return to normal sight.
The research, published October 7 in the New England Journal of Medicine, enrolled 10 legally blind participants. Pitt ophthalmology chair José-Alain Sahel was the study’s first and co-corresponding author. The work involved an international team, with the University of Pittsburgh and UPMC among the Pittsburgh institutions connected to the research.
How the experimental system works
Retinitis pigmentosa damages photoreceptor cells that normally detect light. The study’s strategy was to make surviving retinal ganglion cells respond to light instead. Researchers delivered a gene encoding the light-sensitive protein ChrimsonR into those cells through an injection in the eye. Participants then used goggles with a camera and processor that translated visual scenes into patterns of light intended to activate the modified cells.
The goggles are part of the treatment, not an optional accessory. They convert a camera image into a simplified light pattern, and participants used the system during assessments. That distinction matters for understanding the findings: the study tested a gene therapy-device combination, rather than an injection that restores everyday sight on its own.
What the 10-person study found
Safety was the study’s primary aim. The researchers recorded eye-related adverse events in nine participants; most were mild or moderate, including temporary inflammation and short-lived increases in eye pressure. One severe event—a temporary blockage of the central retinal artery just after injection—resolved within minutes after treatment, according to the paper. These details are part of the safety picture and underscore why the approach remains experimental.
Light sensitivity increased in seven participants, and six met a threshold for a clinically meaningful change; the researchers defined that cutoff from prior literature, and it was not prespecified in the protocol. Some participants could better detect an object, judge where it was, or reach toward it while wearing the goggles. The researchers also reported evidence that visual signals reached the brain. The treatment did not restore normal vision, reading ability or face recognition. Four participants showed consistent gains on multiple real-world tasks over months to years of testing, according to Pitt’s summary of the research.
Why the result is promising—and preliminary
The approach is designed to work without targeting one specific genetic mutation. That could matter because retinitis pigmentosa has many genetic causes, but this study does not establish that every patient would benefit. It was an open-label trial with only 10 participants and was designed primarily to assess safety. More research is needed to understand how durable the changes are, which patients might be candidates, and how benefits compare with risks.
Pitt described the findings as a step toward studying vision restoration, not as a treatment now available to patients. Families seeking care should rely on their eye-care team for individual guidance; the study does not create a clinical service or establish that the system is broadly accessible. The study was funded by GenSight Biologics, according to the journal. The full results and methods are available in the journal article, while Pitt’s research summary explains the goggles and the team’s interpretation.
For Pittsburgh, the work reflects the region’s role in collaborative vision research, linking university investigators, clinical care and international partners. Its immediate contribution is evidence that a combined gene-and-device strategy can produce measurable visual responses in some people with profound vision loss. The next milestone is careful follow-up research—not a promise of restored sight.